BioNano Genomics, Inc. WT EXP 082123 (BNGOW)

Etorro trading 970x250

About BioNano Genomics, Inc. WT EXP 082123

Address:

BioNano Genomics, Inc. WT EXP 082123 News and around…

Latest news about BioNano Genomics, Inc. WT EXP 082123 (BNGOW) common stock and company :

Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications
15 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the American Society of Human Genetics (ASHG) conference lineup of customer posters and presentations featuring OGM. The customer posters and presentations span genetic disease applications including amyotrophic lateral sclerosis (ALS) and postnatal, as well as cancer researc

Bionano: BioDiscovery Acquisition Further Bolsters the Bull Case, Says Oppenheimer
14 Oct, 2021 Yahoo! Finance

Bionano’s (BNGO) profile has grown considerably over the past year, mostly due to the disruptive potential of its genome mapping platform Saphyr. On Tuesday, the company announced it is further adding to its genome analysis capabilities with the acquisition of BioDiscovery, a software company with industry leading analysis tools. These include NxClinical, a software solution for variant analysis. The purchase will cost up to $100 million, consisting of a mix of cash and equity and should be comp

Study Shows the Combination of OGM and NGS with Linked-Reads Detects Significantly More Clinically Relevant Variants Resulting in Higher Success Rates for Resolving Previously Unclassified Subjects in Genetic Disease Research
14 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the publication of a study in which OGM and next-generation sequencing (NGS) with linked-reads were used together to resolve genetic diseases that were previously unclassified after evaluation by whole-exome sequencing (WES) alone. This study, from the University of Californi

Bionano Genomics to Acquire BioDiscovery, Furthering Bionano’s Vision of Creating the Most Comprehensive Variant Analysis Platform in Genomics
12 Oct, 2021 Yahoo! Finance

Designed to accelerate the adoption of optical genome mapping (OGM) with the integration of BioDiscovery’s NxClinical software solution for variant analysis Adds a world-class team, software and bioinformatics capabilities to address a broad range of applications in cancer and genetic diseases Brings potential for significant new growth opportunities in life science research and the clinical setting upon launch of an advanced NxClinical solution that integrates OGM, next-generation sequencing (N

Bionano Genomics Expands Commercial Leadership Team to Accelerate Growth of Saphyr® and Bolster Customer Support and Experience Globally
06 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that the following individuals have joined the Company’s commercial leadership team to help accelerate the global growth of Saphyr and bolster customer support: Amanda Lettmann, Vice President of Global Customer Experience, Amanda Hernandez, Vice President of Global Sales Tra

Largest Clinical Research Study to Date Evaluating Optical Genome Mapping for Analysis of Facioscapulohumeral Muscular Dystrophy Showed Concordance with Southern Blot and Reduced Turnaround Time by 50% as Compared to the Traditional Workflow
29 Sep, 2021 Yahoo! Finance

SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced the publication of the largest clinical research study to date evaluating optical genome mapping (OGM) for facioscapulohumeral muscular dystrophy (FSHD), which concluded that OGM can be performed more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. This study, now available online before print in The Journal of Molecular Diagnostics, describes how OGM

Study Finds the Combination of Optical Genome Mapping and Short-Read Sequencing Provides a Comprehensive Genome Analysis for Lung Cancer Samples and Enables the Discovery of New Biomarkers
16 Sep, 2021 Yahoo! Finance

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for lung cancer samples and enables the discovery of new biomarkers. This study, appearing in the September 7th peer-reviewed issue of Cell Reports describes how the combination of OGM and NGS aids in the detection of structural variants (SVs) in

NuProbe Global Adopts Bionano’s Saphyr® System to Develop Products in Reproductive Health and Oncology Applications
07 Sep, 2021 Yahoo! Finance

SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano’s Saphyr system for optical genome mapping (OGM) to integrate their Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA) technologies for research and product development in the fields of reproductive health and oncology l

Bionano Genomics Announces ESHG Lineup Featuring 11 Customer Presentations of OGM Data Spanning Three Major Clinical Research Areas of Application from 10 Institutions and Six Countries
26 Aug, 2021 Yahoo! Finance

SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the European Society of Human Genetics (ESHG) conference lineup featuring 11 customer presentations of optical genome mapping (OGM) data spanning three major clinical areas of application from 10 institutions and six countries. The clinical application areas represented below cover hematological malignancies, inherited genetic disorders and solid tumor analysis. The presentations are expected to co

BioNano Genomics Scanning for Commercial Adoption
09 Aug, 2021 Yahoo! Finance

Biotechnology companies can either be a hit or a miss. If they have yet to commercialize their technology, investing in one can potentially reap lucrative rewards, especially if the company eventually announces successful widespread implementation of its products. In the case of BioNano Genomics, Inc. (BNGO), the path toward profit production is clear, and the company has been marching toward its target. (See BioNano Genomics stock charts on TipRanks) Bullish on the stock is Jason McCarthy of Ma

Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress
04 Aug, 2021 Yahoo! Finance

226% year-over-year total revenue increase driven by growth in the Saphyr installed baseAll 2021 milestones on trackStrong balance sheet with $333 million in cash as of June 30, 2021Conference call today, Wednesday, August 4, at 4:30 pm ET SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the second quarter ended June 30, 2021 and highlighted recent corporate updates. “We had a strong quarter to cap o

Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021
28 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the second quarter ended June 30, 2021 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, August 4, 2021Time:4:30 p.m. Eastern TimeToll Free:1-877-407-0784Toll/International:1-201-689-8560Conference ID:13722135Webcast:

Bionano Genomics Announces a Record Number of Optical Genome Mapping Presentations Scheduled to Appear at the Annual Cancer Genomics Consortium Meeting from August 1st - 4th, 2021
27 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a record number of optical genome mapping (OGM) presentations scheduled to appear at the annual Cancer Genomics Consortium (CGC) meeting being held from August 1 - 4, 2021. Across this four-day event, the meeting features 10 presentations by Bionano’s Saphyr® customers highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products o

Bionano’s Optical Genome Mapping for Acute Lymphoblastic Leukemia Subjects at the University Hospitals Leuven, Belgium, Has Faster Turnaround Time, Higher Success Rates and Lower Cost per Sample Compared to Traditional Methods
19 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announces a summary of the results obtained by the University Hospitals Leuven, Belgium with optical genome mapping (OGM) with Bionano’s Saphyr® system. An assay was developed for whole genome analysis of acute lymphoblastic leukemia (ALL) subjects which, relative to traditional methods, resulted in a workflow with significantly faster turnaround time, higher success rates, and lower cost per sample. The key benef

Bionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA
14 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA). Below is a summary of the leukemia presentations at the ECA featuring OGM data generated by the Bionano Saphyr system, delivered online from July 3 - 5, 2021 during th

Bionano’s Optical Genome Mapping Extensively Featured at the 2021 European Cytogenomics Conference as a Superior Solution for Genomic Analysis in Leukemia and Genetic Disease Compared to Traditional Techniques
13 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that optical genome mapping (OGM) was extensively featured across a wide range of talks and posters at the 2021 European Cytogenomics Conference (ECA) as a superior solution for genomic analysis in leukemia and genetic disease compared to traditional techniques. At the ECA, there were nine talks and posters featuring OGM presented online from July 3 - 5, 2021 during this virtual event. The conferen

Another Day, Another Buy Rating for Bionano Stock
09 Jul, 2021 Yahoo! Finance

Two months ago, just after Bionano Genomics (BNGO) had reported a bit of an earnings miss, Maxim analyst Jason McCarthy was sufficiently discouraged about the company's prospects that he cut his price target on the San Diego-based cytogenetics specialist's stock by $4 to $10. Two months later, McCarthy is holding firm on that revised prediction, though, and reiterating his "buy" recommendation on the stock as well in a note published yesterday -- and why not? In the two months since he last doub

Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies
07 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two peer-reviewed studies from world renowned scientists and clinicians from prestigious institutions in Europe including Radboud University Medical Center, Cochin Hospital in Paris, Hospices Civils in Lyon and the University Hospital of Clermont-Ferrand were published back-to-back in the American Journal of Human Genetics. One study analyzed the genomes of patients with inherited genetic dise

Bionano Genomics Announces Significant Progress in China with WeHealth Shanghai’s Adoption of Bionano’s Saphyr System and the Demonstration by Various Institutions of Optical Genome Mapping in Reproductive Health and Genetics
06 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr® System for optical genome mapping (OGM) by WeHealth Shanghai, a leading provider of genome analysis services in reproductive health. The adoption was announced at the Structural Variation Symposium in Shanghai, organized with support from the Shanghai Society of Genetics. WeHealth announced the launch of its complete genome-analysis offering

Bionano Genomics’ Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome Mapping (OGM) at the 2021 International Conference of the Board of Genetic Counseling India
02 Jul, 2021 Yahoo! Finance

SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the 6th Annual International Conference of the Board of Genetic Counseling India to be held virtually from July 2nd-4th 2021. Dr. Chaubey has been recognized to present as an invited speaker and will discuss how optical genome mapping (OGM) is enabling a revolution

BioNano Genomics, Inc. WT EXP 082123 (BNGOW) is a NASDAQ Common Stock listed in ,

970x250